Cargando…

Endocrine treatment in advanced prostate cancer: When to start?

Detalles Bibliográficos
Autores principales:	Choudhrie, A. V., Singh, J. C.
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2009
Materias:	Uroscan
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779978/

Ejemplares similares

Prostate cancer treatment does not increase the risk of cardiovascular events
por: Khochikar, Makarand V.
Publicado: (2007)

Defining the role of antioxidants in the prevention of prostate cancer
por: Pathak, Hemant R., et al.
Publicado: (2009)

Rezvilutamide for metastatic castration-sensitive prostate cancer: CHART trial
por: Singh, Kirti
Publicado: (2023)

The role of 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: Is it the new beginning
por: Agrawal, Sumit
Publicado: (2020)

Triple therapy for metastatic castration sensitive prostate cancer: PEACE-1 trial
por: Singh, Kirti
Publicado: (2022)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Intraprostatic injection of botulinum toxin A: A promising treatment for patients with benign prostatic hyperplasia
por: Agrawal, S. K., et al.
Publicado: (2009)

Is incidence of prostate cancer higher in patients with end stage renal disease?
por: Khochikar, Makarand V.
Publicado: (2007)

The current role of Active Surveillance in early prostate cancer
por: Shrinivas, R. P., et al.
Publicado: (2009)

Does dutasteride reduce perioperative blood loss and postoperative complications after transurethral resection of the prostate?
por: Shanmugasundaram, R., et al.
Publicado: (2007)

Safety and efficacy of active surveillance in patients with localized prostate cancer
por: Mavuduru, Ravimohan, et al.
Publicado: (2008)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
por: Jena, Rahul
Publicado: (2020)

Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?
por: Ranjan, Satish Kumar
Publicado: (2020)

L.I.F.T. study: Prostatic urethral lift for the treatment of LUTS associated with BPH
por: Gupta, Saurabh
Publicado: (2014)

Temsirolimus, interferon alfa or both in advanced renal-cell carcinoma: One plus one does not always equal two
por: Grover, S., et al.
Publicado: (2007)

Survival following primary androgen deprivation therapy among men with localized prostate cancer
por: Vasudeva, Pawan, et al.
Publicado: (2008)

Multiparametric magnetic resonance imaging-targeted biopsies in the detection of clinically significant prostate cancer
por: Charalampos, Fragkoulis
Publicado: (2020)

TITAN trial; shifting focus from hormone-refractory to hormone-sensitive prostate cancer
por: Kumar, Gautam
Publicado: (2020)

Benefit of cabazitaxel in previously treated metastatic castration-resistant prostate cancer; CARD trial
por: Mishra, Ankit
Publicado: (2020)

PROMPTS Trial: Screening spinal magnetic resonance imaging in castration-resistant prostate cancer
por: Pattnaik, Soumya Shivasis
Publicado: (2023)

VISION trial: (177)Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
por: Rohith, Gorrepati
Publicado: (2021)

A game changing LATITUDE: Role of abiraterone plus prednisolone in metastatic hormone-sensitive prostate cancer
por: Sharma, Aditya Prakash
Publicado: (2017)

The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
por: Tripathy, Sambit
Publicado: (2021)

STHLM3-MRI study: Role of magnetic resonance imaging-targeted biopsy in prostate cancer screening
por: Gaur, Abhay S.
Publicado: (2022)

LATITUDE: A landmark trial for high-risk metastatic castration-sensitive prostate cancer: Final overall survival analysis
por: Kumar, Gautam
Publicado: (2020)

Transurethral ethanol ablation for symptomatic benign prostatic hyperplasia
por: Gautam, Gagan, et al.
Publicado: (2007)

The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: A pilot study
por: Vasudeva, Pawan, et al.
Publicado: (2008)

ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?
por: Kumar, Naveen
Publicado: (2022)

Comparing outcomes between neoadjuvant hormonal therapy followed by prostatectomy versus upfront prostatectomy in high-risk prostate cancer: The road ahead
por: Bhargava, Priyank
Publicado: (2023)

A novel approach to management of nocturia in patients with benign prostatic hyperplasia
por: Sengottayan, Vengetesh K., et al.
Publicado: (2009)

PROFOUND trial –a new era in targeted therapeutics for prostate carcinoma
por: Tosh, Jyoti Mohan
Publicado: (2022)

Apalutamide: A novel therapy for non metastatic castration-resistant carcinoma prostate
por: Jayasimha, Sudhindra
Publicado: (2018)

What is the role of adjuvant chemotherapy in locally advanced and lymph node-positive bladder cancer after radical cystectomy?
por: Maheshwari, Ruchir, et al.
Publicado: (2009)

First-line maintenance immunotherapy in advanced urothelial cancers: Practice changing implications of the JAVELIN bladder 100 trial
por: Kumaraswamy, Santosh
Publicado: (2021)

Does early orchidopexy reduce risk of testicular cancer?
por: Banerji, John S., et al.
Publicado: (2008)

Thulium laser versus standard transurethral resection of the prostate: A randomized prospective trial
por: Dubey, Deepak, et al.
Publicado: (2008)

PROpel trial: Are PARP inhibitors ready to become the first-line treatment for mCRPC?
por: Gaur, Abhay Singh
Publicado: (2022)

Comparison of multiparametric ultrasound versus multiparametric magnetic resonance imaging for diagnosis of carcinoma prostate: The CADMUS trial
por: Tarigopula, Vivek
Publicado: (2022)

Long-term follow-up results of nivolumab plus cabozantinib versus sunitinib for advanced renal cell cancer: Checkmate 9ER trial
por: Tarigopula, Vivek
Publicado: (2022)

Search for new α1a-adrenoceptor-selective antagonist for treating lower urinary tract symptoms associated with benign prostatic hyperplasia
por: Khurana, Naval, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_u91fk5kohbaq2joosktjlj0oi9